UPDATE: Eli Lilly to build $70M R&D building in Indianapolis
The 130,000-square-foot building will be designed to encourage collaboration among scientists across different disciplines, which the company said is crucial to fostering innovation.
Eli Lilly and Co.
Articles
Elanco president makes case for juiced-up cows in organic age
Jeff Simmons is on a counteroffensive as, increasingly, the drugs that Elanco makes—including antibiotics and productivity enhancers—have come under attack by food activists.
Lilly CEO: Drugmakers getting bum rap
Eli Lilly and Co. CEO John Lechleiter told Wall Street analysts recently that, while there have been “individual huge drug price increases,” the overall cost of drugs is rising very slowly and remains a small part of overall U.S. health care spending.
Lilly predicts higher profits after better-than-expected quarter
Eli Lilly and Co. beat Wall Street’s expectations with its third-quarter profit, prompting the drugmaker to raise its full-year forecast by as much as 20 cents per share.
Pharmaceutical firms losing business to darknet drug deals
For the $300 billion pharmaceutical industry, the rapid growth of illegal underground marketplaces is a serious threat to profits and reputations.
Lilly competitor fails to win FDA backing for diabetes treatment
AstraZeneca Plc didn’t receive U.S. approval for a new diabetes treatment that combines two of its existing drugs. The combination would have competed with Glyxambi from Lilly.
UPDATE: Lilly halts work on potential blockbuster cholesterol drug
Eli Lilly shares plunged nearly 10 percent Monday morning after it said it would stop development of evacetrapib, an experimental cholesterol drug with blockbuster potential.
Lilly expands China drug partnership in growing cancer market
Suzhou, China-based Innovent could receive payments totaling more than $1 billion if the cancer products it develops with Lilly reach certain milestones.
Eskenazi launches $50M effort to take brain care around the world
The safety-net hospital system in Indianapolis will create the Center for Brain Care Innovation and try to use telemedicine and a digital avatar to reach as many as 150,000 Hoosiers and 10 million patients outside Indiana by 2030.
Lilly to add 50 employees at R&D center in New York
The drugmaker is trying to beef up its work on using the immune system to fight cancer. Indianapolis will remain Lilly’s main hub for research and development.
Go figure: As patients’ anger over costs spikes, health care prices barely budge
Patients’ anger over high deductibles and high drug prices is spurring presidential candidates to respond—even as the actual prices of health care services are growing slower than at any time since 1990.
Puerto Rico plans new corporate tax to replace excise levy
Puerto Rico officials are looking to replace an expiring tax with a new levy to draw much-needed revenue from the world’s best-selling medications while seeking to avoid driving U.S. manufacturers such as Eli Lilly and Co. from the commonwealth.
Lilly stock climbs on positive arthritis drug test
A potential rheumatoid arthritis treatment from drugmakers Eli Lilly and Co. and Incyte Corp. fared better than another drug in late-stage testing, Lilly said Tuesday.
Settlement clears way for Lilly to launch once-a-day insulin
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
The Interview Issue: John Lechleiter
John Lechleiter, CEO of Eli Lilly and Co., said the company remained confident about its drug pipeline even after it weathered a string of failed clinical trials.
The Interview Issue: David Contis
Simon Property Group executive David Contis says technology will enhance, not kill, bricks-and-mortar retail.
Analyst: Lilly’s Jardiance diabetes pill could be a $6 billion-a-year blockbuster
It looks like Eli Lilly and Co. finally has a drug that can replace its former stars Zyprexa and Cymbalta. The most bullish analysts think Jardiance can surpass those $5 billion-a-year blockbusters.
Lilly stock performs big despite analyst projections
Analysts have consistently given the Indianapolis-based company some of the lowest ratings among a group of 16 large drugmakers, but Lilly shares have been on a five-year rally.
Lilly’s heart study sets up showdown with Novo’s Victoza
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
Jardiance study lifts Lilly shares to 15-year high
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.